IVF

INVO Fertility, Inc. Common Stock

1.31 USD
-0.11
7.75%
At close Jun 13, 4:00 PM EDT
After hours
1.30
-0.01
0.76%
1 day
-7.75%
5 days
-10.27%
1 month
-33.84%
3 months
-65.97%
6 months
-86.69%
Year to date
-87.00%
1 year
-88.48%
5 years
-99.82%
10 years
-99.82%
 

About: INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic; The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell; and The Therapeutics segment consisting of financial information relating to acquired subsidiary, NTI.

Employees: 32

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

38% more capital invested

Capital invested by funds: $165K [Q4 2024] → $228K (+$62.8K) [Q1 2025]

12.47% more ownership

Funds ownership: 4.56% [Q4 2024] → 17.03% (+12.47%) [Q1 2025]

33% less funds holding

Funds holding: 9 [Q4 2024] → 6 (-3) [Q1 2025]

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Research analyst outlook

We haven’t received any recent analyst ratings for IVF.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
Neutral
GlobeNewsWire
3 weeks ago
INVO Fertility Announces First Quarter 2025 Financial Results
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics
INVO Fertility Announces First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 month ago
INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA
SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics, today announced fourth quarter and full year 2024 financial results.
INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA
Charts implemented using Lightweight Charts™